Immunotherapy / PD-1 inhibitorFDA-approvedFirst-line
Keytruda
Generic name: pembrolizumab
How it works
Blocks the PD-1 protein on immune cells, allowing them to recognize and attack cancer cells.
Cancer types
Lung Cancer— All patients
Melanoma— All patients
Efficacy
Studies show that patients treated with Keytruda have a median overall survival of approximately 17.1 months.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Combining Chemotherapy and Immunotherapy for Lung Cancer | Lung Cancer | observational | — | Source → |
| Testing New Treatments for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing a New Treatment for Brain Metastases from Non-small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing a New Lung Cancer Treatment Combination | Lung Cancer | phase-3 | — | Source → |
| Testing a New Imaging Agent for Lung Cancer Treatment Response | Lung Cancer | phase-1 | — | Source → |
| Testing MQ719 with and without Pembrolizumab in Solid Tumor Cancer Patients | Melanoma | phase-1 | — | Source → |
| Testing a Combination of Vaccines and Immunotherapy for Advanced Lung and Head and Neck Cancers | Lung Cancer | phase-1 | — | Source → |
| Testing Sacituzumab Tirumotecan and Pembrolizumab in Advanced Solid Tumors | Lung Cancer | phase-1 | — | Source → |
| EIK1001 Combination Therapy for Stage 4 Non-Small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing Folfirinox and Pembrolizumab for Resectable Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Testing Zongertinib in Combination with Chemotherapy for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| New Study Examines Treatment for Advanced Triple-Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Pembrolizumab's Effectiveness in Lung Cancer Treatment | Lung Cancer | review | — | Source → |
| Testing Sitagliptin and Pembrolizumab in Advanced Cancer | Melanoma | phase-1 | — | Source → |
| Immune Checkpoint Inhibitors for Lung Cancer: Cost-Effectiveness Study | Lung Cancer | observational | Pembrolizumab demonstrated the longest median overall survival (OS) at 15.49 months in stage IV, and 34.64 months in stage III. | Source → |
| Pembrolizumab and Chemotherapy for Early-stage Triple-negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Evaluating a Combination Treatment for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing a New Treatment for Non-Small-Cell Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Testing Pembrolizumab and Paclitaxel for Recurring Triple-Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Study Examines Niraparib-Plus-Pembrolizumab for Lung Cancer Maintenance Therapy | Lung Cancer | phase-3 | The median progression-free survival was 5.55 months for both treatment arms. | Source → |
| Testing ILKN421H and Pembrolizumab for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Managing Skin Reactions to Cancer Treatment with Methotrexate | Melanoma | observational | — | Source → |
| Immunotherapy Options for Colorectal Cancer | Colorectal Cancer | review | Pembrolizumab has a well-characterized long-term safety profile and superior progression-free and overall survival versus chemotherapy. | Source → |
| Testing a New Treatment for Advanced Solid Tumors | Breast Cancer | phase-1 | — | Source → |
| Testing New Treatment for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Pembrolizumab in Black Patients with Non-Small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing Fianlimab and Cemiplimab for Melanoma Prevention | Melanoma | phase-3 | — | Source → |
| Pembrolizumab Rechallenge Shows Promise in Lung Cancer | Lung Cancer | observational | — | Source → |
| Testing a Vaccine and Medicine Combination for Advanced Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Immunotherapy Helps Patient with Advanced Pancreatic Cancer | Pancreatic Cancer | observational | — | Source → |
| Testing ASTX660 and Pembrolizumab in Advanced Cancer Patients | Breast Cancer | phase-1 | — | Source → |
| Testing a New Combination Treatment for Metastatic Melanoma | Melanoma | phase-1 | — | Source → |
| Rare Eye Inflammation Linked to Cancer Treatment | Melanoma | observational | — | Source → |
| Testing Combination Therapies for Advanced Prostate Cancer | Prostate Cancer | phase-1 | — | Source → |
| Testing NEO-201 in Combination with Pembrolizumab for Solid Tumors | Lung Cancer | phase-1 | — | Source → |
| Testing New Combination Therapy for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Pembrolizumab for Advanced Breast Cancer: A Phase 2 Clinical Trial | Breast Cancer | phase-2 | — | Source → |
| Testing Focused Ultrasound to Open Blood-Brain Barrier for Lung Cancer Brain Metastases | Lung Cancer | phase-3 | — | Source → |
| Combining Pembrolizumab and Olaparib for Metastatic Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Pancreatic Cancer Trial Examines Combination Treatment | Pancreatic Cancer | phase-2 | — | Source → |
| Fecal Microbiota Transplant and Anti-PD-1 Therapy for Metastatic Colorectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| New Lung Cancer Treatment Shows Promise | Lung Cancer | preclinical | Six patients (54.5%) achieved pathological complete response. | Source → |
| Testing Pembrolizumab for Lung Cancer Treatment | Lung Cancer | phase-2 | — | Source → |
| Immune Checkpoint Inhibitors for Lung Cancer: Cost-Effectiveness Study | Lung Cancer | observational | Pembrolizumab demonstrated the longest median overall survival (OS) at 15.49 months in stage IV, and 34.64 months in stage III. | Source → |
| Pembrolizumab Study for Advanced Solid Tumors | Breast Cancer | phase-2 | — | Source → |
| Pembrolizumab vs. Observation in Triple-Negative Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Rare Side Effect of Cancer Treatment: Muscle Weakness Linked to Pembrolizumab | Lung Cancer | review | — | Source → |
| Cryotherapy May Enhance Lung Cancer Treatment | Lung Cancer | phase-2 | — | Source → |
| Testing a New Combination Therapy for Advanced Solid Tumors | Ovarian Cancer | phase-1 | — | Source → |
| Investigating Petosemtamab for Metastatic Non-Small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing Pembrolizumab Alone or With Chemotherapy for Non-Small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing a New Cancer Treatment Combination in Solid Tumors | Lung Cancer | phase-1 | — | Source → |
| Pembrolizumab and Chemotherapy Combination for Advanced Non-Small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Rare Cancer Patient Experiences Two Types of Joint Pain | Lung Cancer | observational | — | Source → |
| Comparing Treatments for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Pembrolizumab and Cryoablation for Metastatic Breast Cancer | Breast Cancer | phase-1 | — | Source → |
| Testing a Combination Therapy for Early-stage Triple-negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Monitoring Blood Markers in Lung Cancer Patients on Immunotherapy | Lung Cancer | phase-2 | — | Source → |
| Pembrolizumab May Help Treat Rare Breast Cancer | Breast Cancer | observational | — | Source → |
| Combining Gut Bacteria and Immunotherapy Shows Promise in Cancer Treatment | Lung Cancer | phase-1 | In ICI-naïve NSCLC (n=12) with programmed death-ligand 1 (PD-L1) >50%, the overall response rate (ORR) and disease control rate (DCR) were 58% and 75%, respectively. | Source → |
| Pembrolizumab and Chemotherapy Combination Study for Stage IV Non-Small Cell Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Combination Therapy for Ovarian Cancer: A Phase II Clinical Trial | Ovarian Cancer | phase-2 | — | Source → |
| Testing Combination Immunotherapy for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing a New Cancer Treatment, HLX17, Compared to Keytruda in Solid Tumors | Lung Cancer | phase-1 | — | Source → |
| Talabostat and Pembrolizumab Show Some Effectiveness in Treating Aggressive Prostate Cancer | Prostate Cancer | phase-2 | The composite response rate was 20% (95% CI 7.7% to 38.6%) and the objective response rate was 13% (95% CI 3.8% to 30.7%). | Source → |
| Pembrolizumab Shows Promise in Treating Advanced Anal Cancer | Colorectal Cancer | observational | The objective response rate was 13.5%, with two complete and three partial responses. | Source → |
| Combination Therapy for Metastatic Melanoma and Renal Cell Carcinoma | Melanoma | phase-2 | — | Source → |
| Pembrolizumab-Chemotherapy for Lung Cancer: Real-World Study in Serbia | Lung Cancer | observational | Median progression-free survival was 7.03 months (95% CI, 4.81-9.26). | Source → |
| Olaparib and Pembrolizumab in Breast Cancer Treatment | Breast Cancer | phase-2 | — | Source → |
| Combination Therapy for Advanced Lung Cancer: A Phase 3 Clinical Trial | Lung Cancer | phase-3 | — | Source → |
| Melanoma Treatment Trial Investigates Combination Therapy | Melanoma | phase-2 | — | Source → |
| Evaluating a New Treatment Combination for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Longer Pembrolizumab Therapy May Improve Survival in Advanced Melanoma | Melanoma | observational | Long-term therapy significantly reduced overall mortality (HR = 0.41, 95% CI: 0.27-0.62) compared with short-term therapy. | Source → |
| Combination Therapy for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Monitoring a Cancer Drug's Effectiveness in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Pembrolizumab for Metastatic Prostate Cancer After Enzalutamide Treatment | Prostate Cancer | phase-2 | — | Source → |
| Combination Therapy for Extensive-stage Small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing New Treatments for Advanced Triple-Negative Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Testing a New Combination Therapy for Advanced Non-small Cell Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Testing Pembrolizumab in Children with Advanced Cancer | Melanoma | phase-1 | — | Source → |
| Study of New Treatments for Triple Negative Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Ovarian Cancer Treatment Trial Investigates New Combination Therapy | Ovarian Cancer | phase-1 | — | Source → |
| Pembrolizumab and Chemotherapy May Improve Survival in Lung Cancer Patients | Lung Cancer | meta-analysis | Pembrolizumab plus chemotherapy improved overall survival (HR 0.67, 95% CI 0.46-0.96). | Source → |
| Testing Ivonescimab for Lung Cancer Treatment | Lung Cancer | phase-3 | — | Source → |
| Testing Chemotherapy, Pembrolizumab, and Radiation for Triple Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Testing Lenvatinib and Pembrolizumab for Advanced Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Evaluating GEN1046 for Recurrent Non-Small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing Rilvegostomig and Pembrolizumab for Lung Cancer Treatment | Lung Cancer | phase-3 | — | Source → |
| Comparing a Proposed Biosimilar to Keytruda in Melanoma Patients | Melanoma | phase-1 | — | Source → |
| Testing Rigosertib and Pembrolizumab for Advanced Melanoma | Melanoma | phase-2 | — | Source → |
| Testing Fianlimab and Cemiplimab in Melanoma Patients | Melanoma | phase-3 | — | Source → |
| Pembrolizumab Effectiveness in Advanced Lung Cancer | Lung Cancer | observational | Median progression-free survival was 8.7 months, and median overall survival was 18.0 months. | Source → |
| Testing Pembrolizumab and Lenvatinib for Stage III Melanoma | Melanoma | phase-2 | — | Source → |
| Testing LNS8801 and Pembrolizumab in Advanced Melanoma | Melanoma | phase-2 | — | Source → |
| Comparing Treatments for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing Treatments for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Study of Pembrolizumab and Radiation Before Breast Cancer Surgery | Breast Cancer | phase-1 | — | Source → |
| Assessing Pembrolizumab and Sacituzumab Tirumotecan in Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing Pembrolizumab and 177Lu-PSMA-617 in Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Testing Ramucirumab Plus Pembrolizumab for Stage IV Non-Small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Pembrolizumab Monotherapy for Advanced Lung Cancer in Vietnam | Lung Cancer | observational | The overall response rate was 60.3%, and the disease control rate was 79.5%. | Source → |
| Evaluating Pumitamig vs. Pembrolizumab for Advanced Non-Small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| High Dose Radiation Therapy and Immunotherapy for Metastatic Triple Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Testing Immunotherapy in Advanced Colorectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Testing Alpelisib and Pembrolizumab in Advanced Breast Cancer and Melanoma | Breast Cancer | phase-1 | — | Source → |
| Pembrolizumab Linked to Higher Pneumonitis Risk in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Testing a New Treatment for Advanced Solid Tumors | Breast Cancer | phase-1 | — | Source → |
| Melanoma Treatment Trial: Intismeran Autogene and Pembrolizumab | Melanoma | phase-2 | — | Source → |
| Combining Chemotherapy and Pembrolizumab for Triple Negative Breast Cancer | Breast Cancer | phase-1 | — | Source → |
| Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Testing Pembrolizumab in Advanced Melanoma Patients | Melanoma | phase-1 | — | Source → |
| Evaluating Acasunlimab and Pembrolizumab for Advanced Melanoma | Melanoma | phase-2 | — | Source → |
| Evaluating GB1211 and Pembrolizumab in Metastatic Melanoma and Head and Neck Cancer | Melanoma | phase-2 | — | Source → |
| Olomorasib and pembrolizumab combination tested in G12C NSCLC patients | Lung Cancer | phase-1/2 | — | Source → |
| Study of Sigvotatug Vedotin and Pembrolizumab in Non-Small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing New Cancer Treatment in Combination with Existing Medications | Lung Cancer | phase-1 | — | Source → |
| Advanced Melanoma Treatment Trial Evaluates Combination of Three Study Medicines | Melanoma | phase-3 | — | Source → |
| EIK1005 Clinical Trial for Advanced Solid Tumors | Colorectal Cancer | phase-1 | — | Source → |
| Comparing Two Cancer Treatments in Lung Cancer Patients | Lung Cancer | observational | The median progression-free survival was 9.93 months for pembrolizumab and 5.33 months for atezolizumab. | Source → |
| Melanoma Trial Investigates Combination Therapy | Melanoma | phase-3 | — | Source → |
| Pembrolizumab vs. Chemotherapy in Advanced Colorectal Cancer | Colorectal Cancer | phase-3 | — | Source → |
| Pembrolizumab Helps Patient with Advanced Colon Cancer | Colorectal Cancer | observational | — | Source → |
| Testing Olaparib and Pembrolizumab for Advanced Uveal Melanoma | Melanoma | phase-2 | — | Source → |
| Testing New Combinations for Chronic Myeloid Leukemia | Leukemia | phase-2 | — | Source → |
| Vaccine Therapy and Pembrolizumab for Advanced Ovarian Cancer | Ovarian Cancer | phase-1 | — | Source → |
| Testing a Combination Treatment for Advanced Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Rare kidney disease linked to lung cancer treatment | Lung Cancer | observational | — | Source → |
| Pembrolizumab Dosage: Weight-Based and Fixed-Dose Compared in Lung Cancer | Lung Cancer | observational | Median overall survival was 18.4 months for fixed-dose pembrolizumab and 23.2 months for weight-based pembrolizumab. | Source → |
| Testing Adoptive Cell Therapy for Metastatic Melanoma | Melanoma | phase-2 | — | Source → |
| Melanoma Treatment Trial Investigates Combination of NeoVax and Immunotherapies | Melanoma | phase-1 | — | Source → |
| Testing Nemtabrutinib and Pembrolizumab for Richter Transformation | Leukemia | phase-2 | — | Source → |
| New Cancer Treatment Shows Promise for Lung Cancer Patients | Lung Cancer | preclinical | In treatment-naive patients receiving doublet therapy, confirmed objective response rate (ORR) was 54.8%, median duration of response (mDOR) was 20.1 months, and median progression-free survival (mPFS) was 11.2 months. | Source → |
| Pembrolizumab and Intismeran Autogene in Non-Small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Comparing Subcutaneous and Intravenous Pembrolizumab for Cancer Treatment | Lung Cancer | phase-2 | — | Source → |
| Combining Immunotherapy and Chemotherapy for Lung Cancer with Brain Metastases | Lung Cancer | phase-2 | The intracranial objective response rate was 46.2% (95% CI, 19.2-74.8), with 6 patients achieving partial response. | Source → |
| Study of Sacituzumab Tirumotecan and Pembrolizumab for Triple-Negative Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Adjuvant Therapy Patterns After Chemoimmunotherapy for Early-Stage Triple-Negative Breast Cancer | Breast Cancer | observational | — | Source → |
| Evaluating Adagrasib in Advanced Non-Small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing Sonidegib and Pembrolizumab in Advanced Solid Tumors | Lung Cancer | phase-1 | — | Source → |
| Pembrolizumab and Chemotherapy for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Study of Combination Therapy for Metastatic Colorectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Pembrolizumab for Advanced Cancer with Genomic Instability | Breast Cancer | phase-2 | — | Source → |
| Study of Adagrasib and Pembrolizumab in Untreated Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| New Treatment Combination for Triple-Negative Breast Cancer Being Tested | Breast Cancer | phase-3 | — | Source → |
| Pembrolizumab and Anetumab Ravtansine for Mesothelioma Treatment | Lung Cancer | phase-1 | — | Source → |
| Pembrolizumab and Radiation Therapy for Mesothelioma | Lung Cancer | phase-1 | — | Source → |
| Personalized Vaccine Trial for Advanced Solid Tumors | Breast Cancer | phase-1 | — | Source → |
| Comparing a Proposed Lung Cancer Treatment to a Standard Medication | Lung Cancer | phase-3 | — | Source → |
| New Lung Cancer Treatment Combination Shows Promise | Lung Cancer | phase-3 | — | Source → |
| Testing GT103 with Pembrolizumab for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Ovarian Cancer Treatment Trial: Pembrolizumab and Paclitaxel Combination | Ovarian Cancer | phase-3 | — | Source → |
| Testing Pembrolizumab as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Evaluating Pembrolizumab and Enzalutamide in Metastatic Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Testing a Combination Treatment for Early-stage Triple-negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Non-small Cell Lung Cancer Treatment Trial Recruiting Participants | Lung Cancer | phase-3 | — | Source → |
| Testing Immunotherapy After Surgery for High-Risk Melanoma | Melanoma | phase-3 | — | Source → |
| Testing a New Treatment for Acute Myeloid Leukemia | Leukemia | phase-2 | — | Source → |
| Personalized Cancer Vaccine Shows Long-Term Benefit | Melanoma | phase-2 | The vaccine reduced the risk of melanoma recurrence or death by roughly 49%. | Source → |
| Combining Immunotherapy and Chemotherapy in Melanoma Treatment | Melanoma | phase-2 | The overall response rate was 43%, and the disease control rate was 53%. | Source → |
| Combining Two Cancer Treatments Shows Promise in Advanced Melanoma | Melanoma | phase-1/2 | Among 20 patients treated in phase 2, the overall response rate was 45%, median progression-free survival was 6.6 months, and median overall survival was 29.5 months. | Source → |
| Combination Therapy Fails to Show Benefit in Melanoma Study | Melanoma | phase-3 | — | Source → |
| Pembrolizumab's Effect on New Skin Cancers in Melanoma Patients | Melanoma | phase-3 | The median recurrence-free survival with new primary melanoma counted as an event was 59.2 months with placebo and not reached with pembrolizumab (hazard ratio, 0.65; 95% CI, 0.52-0.80). | Source → |
| Pembrolizumab Shows Promise in Treating Desmoplastic Melanoma | Melanoma | phase-2 | The pathological complete response rate was 71% (95% confidence interval, 51-87%; P < 0.001). | Source → |
| Pembrolizumab Monotherapy in Advanced Lung Cancer | Lung Cancer | observational | The median progression-free survival was 5.6 months, with 6-month and 60-month PFS rates of 47.4% and 5.1%, respectively. | Source → |
| Comparing Liver Safety of Two Cancer Treatments | Lung Cancer | observational | — | Source → |
| New Study Examines Blood Test and Protein Marker in Lung Cancer Treatment | Lung Cancer | observational | Low baseline SII was significantly associated with superior progression-free survival (PFS) (p = 0.031) and overall survival (OS) (p = 0.004). | Source → |
| Rare Side Effect of Cancer Treatment Managed with New Approach | Melanoma | observational | — | Source → |
| Immunochemotherapy Impact on Surgery Outcomes in Early Triple-Negative Breast Cancer | Breast Cancer | observational | — | Source → |
| Rare Complications from Long-Term Cancer Treatment | Lung Cancer | observational | — | Source → |
| Comparing Two Cancer Treatments in Lung Cancer Patients | Lung Cancer | phase-3 | The pathological complete response rate was 43.8% in the pembrolizumab group. | Source → |
| Immunotherapy Helps Patient with Advanced Colorectal Cancer | Colorectal Cancer | observational | — | Source → |
| Evaluating a New Treatment for High-Risk Melanoma | Melanoma | phase-2 | — | Source → |
| Pembrolizumab dosing schedule may be safe and effective for breast cancer patients | Breast Cancer | observational | Rates of grade 3 or higher immune-related adverse events were lower in extended-interval dosing (4%) compared to standard-interval dosing (20%). | Source → |
| Rare but Fatal Heart Condition Linked to Cancer Treatment | Lung Cancer | review | — | Source → |
| Combining Virus and Immunotherapy Shows Promise in Lung Cancer | Lung Cancer | phase-1/2 | Partial responses were seen in two patients with prior acquired anti-PD-1 resistance and disease stabilization in six patients, giving a clinical benefit rate of 80%. | Source → |
| Rare Side Effect of Cancer Treatment Causes Nerve Damage | Melanoma | observational | — | Source → |
| New Treatment Options for Advanced Ovarian Cancer Patients | Ovarian Cancer | phase-3 | — | Source → |
| Combination Therapy Fails to Improve CLL Response, but Activates CD8 T Cells | Leukemia | phase-2 | There was 1 complete response and 9 partial responses in 10 patients evaluable for response. | Source → |
| Rare Lung Condition Linked to Cancer Treatment | Lung Cancer | observational | — | Source → |
| Melanoma Treatment Trial: Intismeran Autogene and Pembrolizumab | Melanoma | phase-3 | — | Source → |
| Pembrolizumab treatment shows promise for rare lung cancer | Lung Cancer | observational | — | Source → |
| Antibiotics, Steroids, and PPIs May Affect Lung Cancer Treatment | Lung Cancer | observational | — | Source → |
| Rare Lung Injury in Cancer Treatment | Lung Cancer | observational | — | Source → |
| Pembrolizumab Shows Promise in Advanced Pancreatic Cancer | Pancreatic Cancer | observational | The patient had a durable response of 13 months. | Source → |
| Pembrolizumab as Adjuvant Treatment for Early-Stage Lung Cancer | Lung Cancer | phase-3 | Pembrolizumab extended life years (1.55) and quality-adjusted life years (1.19). | Source → |
| Pembrolizumab Slows Ovarian Cancer Growth in Lab Experiments | Ovarian Cancer | lab-study | — | Source → |
| NK Cells Respond to Anti-PD-1 Therapy in Melanoma Patients | Melanoma | lab-study | — | Source → |
| Pembrolizumab's Effectiveness in Common Cancers | Melanoma | review | — | Source → |
| Pembrolizumab Works Well for Older Lung Cancer Patients | Lung Cancer | observational | No significant differences in median time on treatment (12.7 vs. 14.3 months) or median overall survival (18.2 vs. 27.4 months) were observed between older and younger groups. | Source → |
| Rare Skin Condition Linked to Cancer Treatment | Lung Cancer | observational | — | Source → |
| Rare Side Effect of Cancer Treatment: Encephalomyelitis After Immunotherapy | Melanoma | observational | — | Source → |
| Pembrolizumab Side Effect Treated with Efgartigimod | Melanoma | observational | — | Source → |
| Pembrolizumab treatment shows promise for ovarian cancer patients | Ovarian Cancer | phase-2 | Major pathologic responses were observed in 27% of patients (95%CI 14-46). | Source → |
| Pembrolizumab Extends Survival in Melanoma Patients | Melanoma | phase-3 | At 48 months, RFS rates were 71.3% for pembrolizumab and 58.3% for placebo, and DMFS rates were 81.0% and 70.1%, respectively. | Source → |
| Pembrolizumab as Adjuvant Therapy for High-Risk Melanoma | Melanoma | phase-3 | The number needed to treat (NNT) for recurrence-free survival was 5.3, and for distant metastasis-free survival was 7.8. | Source → |
| Pembrolizumab Side Effects in Lung Cancer Patients | Lung Cancer | observational | The progression-free survival was significant longer in stage IV NSCLC patients with irTD than in those who did not (44.72 weeks vs. 27.79 weeks). | Source → |
| Pembrolizumab May Help Some Advanced Prostate Cancer Patients | Prostate Cancer | phase-2 | 38.9% of patients showed a 50% or greater decline in PSA. | Source → |
| Combination Therapy Shows Promise for Untreated Melanoma Brain Metastases | Melanoma | phase-2 | The brain metastasis response rate was 54.1% (95% CI, 36.9 to 70.5). | Source → |
| Pembrolizumab treatment for elderly lung cancer patients | Lung Cancer | observational | The median overall survival was 14.6 months in the pembrolizumab alone group and 20.3 months in the pembrolizumab plus chemotherapy group. | Source → |
| Combination Therapy Shows Promise in Treating Advanced Lung and Skin Cancer | Melanoma | phase-2 | For the secondary refractory metastatic non-small cell lung cancer cohort, the ORR was 14%, median PFS was 5.85 months, and median OS was 14.4 months. For the secondary refractory metastatic cutaneous melanoma cohort, the ORR was 24%, median PFS was 4.44 months, and median OS was 21.9 months. | Source → |
| Combining Immunotherapy with Lanreotide for Advanced Neuroendocrine Tumors | Pancreatic Cancer | phase-1/2 | Among GI-NETs, the clinical benefit rate was 50% and the median progression-free survival was 8.5 months. | Source → |
| Pembrolizumab-Induced Lung Injury in Cancer Patients | Melanoma | observational | — | Source → |
| Brazilian Study Examines Cost of New Melanoma Treatments | Melanoma | observational | — | Source → |
| Rare Side Effect of Cancer Treatment: Pancreatitis | Pancreatic Cancer | observational | — | Source → |
| Pembrolizumab Can Cause Colitis in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Combining Cryoablation with Immunotherapy Improves Lung Cancer Outcomes | Lung Cancer | observational | Group A demonstrated a higher ORR (75.0% vs. 61.1%), longer median OS (28.1 months vs. 24.2 months), and longer median PFS (12.8 months vs. 8.4 months) compared to Group B. | Source → |
| Testicular Cancer Metastasis Responds to Immunotherapy | Colorectal Cancer | observational | He maintains complete clinical response after 28 months. | Source → |
| Pembrolizumab Helps Patient with Advanced Colon Cancer | Colorectal Cancer | observational | — | Source → |
| Combining Immunotherapy and Chemotherapy for Rare Bladder and Prostate Cancers | Prostate Cancer | preclinical | The overall response rate was 43% for cohort 1 and 57% for cohort 2. | Source → |
| Pembrolizumab treatment helps patient with advanced pancreatic cancer | Pancreatic Cancer | observational | — | Source → |
| Immune Cells May Contribute to Kidney Damage from Cancer Treatment | Lung Cancer | lab-study | — | Source → |
| Combining Chemotherapy and Immunotherapy for Advanced Ovarian Cancer | Ovarian Cancer | phase-2 | Median progression-free survival was 14.88 months, and median overall survival was 57.43 months. | Source → |
| Pembrolizumab Improves Surgery Outcomes for Advanced Ovarian Cancer | Ovarian Cancer | phase-2 | The complete resection rate was 74% in patients who received pembrolizumab, exceeding the prespecified ≥50% threshold. | Source → |
| Pembrolizumab Efficacy in Older Lung Cancer Patients | Lung Cancer | observational | The median overall survival was 20.5 months. | Source → |
| Selpercatinib May Cause Severe Hypersensitivity in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Pembrolizumab and Epacadostat Tested in Ovarian Cancer | Ovarian Cancer | phase-2 | The overall response rate was 21% within 7 months of study entry. | Source → |
| Pembrolizumab Improves Survival in Early-Stage Triple-Negative Breast Cancer | Breast Cancer | phase-3 | The hazard ratios for event-free survival were 0.70 (0.38-1.31), 0.92 (0.39-2.20), 0.52 (0.32-0.82), and 1.24 (0.69-2.23) across different residual cancer burden categories. | Source → |
| New Cancer Treatment May Offer Cost Savings for Patients | Lung Cancer | phase-3 | — | Source → |
| Pembrolizumab 400 mg every 6 weeks shows promise in treating advanced melanoma | Melanoma | phase-1 | The objective response rate was 50.5% (95% CI: 40.4-60.6). | Source → |
| Pembrolizumab Dosage Study in Lung Cancer Patients | Lung Cancer | observational | The overall survival rate was 36.6% in the fixed-dose group and 37.7% in the weight-based dose group. | Source → |
| Immunotherapy Shows Promise for Advanced Colorectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| New Options for Lung Cancer Treatment After Surgery | Lung Cancer | phase-3 | Improved disease-free survival and, in case of PD-L1 at least 50%, also improved overall survival for atezolizumab compared to best supportive care. | Source → |
| Pembrolizumab in Prostate Cancer: New Combination Therapies Show Promise | Prostate Cancer | review | — | Source → |
| Pembrolizumab Therapy and Cardiovascular Risks | Melanoma | review | — | Source → |
| Rare Skin Reaction Linked to Cancer Treatment | Melanoma | observational | — | Source → |
| Diabetes May Affect Efficacy of Cancer Treatment | Lung Cancer | observational | Patients with diabetes had a median progression-free survival of 5.9 months and overall survival of 12 months, compared to 7.1 months and 21 months for those without diabetes. | Source → |
| Testing Immunotherapy Before Surgery for Colon Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Long-term Survival Benefit of Pembrolizumab in Advanced Melanoma | Melanoma | phase-3 | Median overall survival was 32.7 months for pembrolizumab versus 15.9 months for ipilimumab. | Source → |
| New Cancer Treatment Tested in Ovarian Cancer Patients | Ovarian Cancer | phase-3 | — | Source → |
| Pembrolizumab Shows Promise for Inoperable Desmoplastic Melanoma | Melanoma | phase-2 | — | Source → |
| mRNA Vaccine May Help Prevent Melanoma Recurrence | Melanoma | phase-2 | — | Source → |
| Rare Kidney Damage Linked to Cancer Treatment | Lung Cancer | observational | — | Source → |
| Pembrolizumab as Adjuvant Treatment for Melanoma: Cost-Effectiveness Study | Melanoma | phase-3 | Pembrolizumab increased total costs by $80,423 and provided gains of 1.17 quality-adjusted life years (QALYs) and 1.24 life years (LYs) over lifetime. | Source → |
| Re-sensitizing Prostate Cancer to Treatment with a New Approach | Prostate Cancer | phase-1 | — | Source → |
| Tumor Burden Predicts Survival in Lung Cancer Patients | Lung Cancer | phase-2 | Tumor burden below the baseline burden throughout therapy was associated with a median OS of 26.8 months, compared to 7.6 months for those with an increase in tumor burden. | Source → |
| Melanoma Patients' Outcomes After Failed Anti-PD-1 Therapy | Melanoma | observational | The overall response rate to BRAF/MEKi was 75%, 3/4. | Source → |
| Pembrolizumab Monotherapy in Triple-Negative Breast Cancer: Biomarkers for Response | Breast Cancer | phase-2 | — | Source → |
| Rare Side Effect of Cancer Treatment: Immune-Mediated Gastritis | Lung Cancer | observational | — | Source → |
| Pembrolizumab Cost-Effectiveness in Colorectal Cancer | Colorectal Cancer | phase-3 | — | Source → |
| Pembrolizumab treatment in older patients with mismatch repair-deficient colorectal cancer | Colorectal Cancer | observational | Median progression-free survival was 21 months. | Source → |
| New Cancer Treatment Shows Promise in Resistant Melanoma | Melanoma | phase-1/2 | — | Source → |
| Pembrolizumab Effectiveness in Advanced Lung Cancer | Lung Cancer | meta-analysis | Pembrolizumab in combination with chemotherapy was superior to chemotherapy in terms of overall survival (HR=0.60, 95%CI:0.50-0.73), progression-free survival (HR=0.47, 95%CI:0.38-0.58), and objective response rate (OR=3.22, 95%CI:2.57-4.03). | Source → |
| Antibodies in Cancer Patients May Affect Treatment with Pembrolizumab | Melanoma | lab-study | Those melanoma patients with the highest levels (>75% percentile, n = 5) of pembrolizumab-F(ab')2 reactive AHA had significantly better overall survival post pembrolizumab treatment (p = 0.039). | Source → |
| Rare Cancer Patient Shows Response to Immunotherapy | Melanoma | observational | — | Source → |
| Pembrolizumab treatment shows promise for some lung cancer patients | Lung Cancer | observational | — | Source → |
| Detecting Cancer Cells in Blood May Help Guide Treatment for Some Breast Cancer Patients | Breast Cancer | phase-2 | — | Source → |
| Combination Cancer Treatment Tested in Japanese Patients | Lung Cancer | phase-1 | The objective response rate was 33.3%. | Source → |
| Pembrolizumab Improves Survival in Melanoma Patients | Melanoma | phase-3 | Pembrolizumab significantly improved distant metastasis-free survival (hazard ratio [HR] 0·64, 95% CI 0·47-0·88, p=0·0029) versus placebo. | Source → |
| Pembrolizumab Therapy Shows Promise for Advanced Colorectal Cancer | Colorectal Cancer | observational | The lymph nodes reduced markedly after the therapy. | Source → |
| Rare kidney problem linked to cancer treatment | Lung Cancer | observational | — | Source → |
| Pembrolizumab Effectiveness and Safety in Japanese Melanoma Patients | Melanoma | observational | The overall objective response rate was 16.5% at the 1-year follow-up. | Source → |
| Rare Skin Reaction Linked to Cancer Treatment | Melanoma | observational | — | Source → |
| Combining Lenvatinib and Pembrolizumab for Advanced Melanoma | Melanoma | phase-2 | The overall response rate was 21.4% in the total population, with 33.3% in patients who had previously received anti-PD-1 plus anti-CTLA-4 therapy. | Source → |
| Using Computer Models to Improve Cancer Drug Research | Lung Cancer | review | — | Source → |
| Pembrolizumab treatment for elderly lung cancer patients | Lung Cancer | phase-2 | The median progression-free survival was 9.6 months. | Source → |
| Rare Brain Infection Found in Cancer Patient on New Treatment | Lung Cancer | observational | — | Source → |
| Rare Blood Cancer Linked to Immunotherapy Treatment | Leukemia | observational | — | Source → |
| Pembrolizumab Improves Outcomes in Triple-Negative Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Monitoring Cancer Treatment with PET Scans | Breast Cancer | observational | — | Source → |
| Rare Neurotoxicity Side Effect of Cancer Treatment | Lung Cancer | observational | — | Source → |
| Combining Pembrolizumab with microRNA-20b-5p May Improve Cancer Treatment | Lung Cancer | lab-study | — | Source → |
| Pembrolizumab Monotherapy for Lung Cancer in Elderly or Those with Poor Health | Lung Cancer | observational | The median progression-free survival was 4.4 months for patients with poor health and 5.3 months for those aged 75 or older. | Source → |
| Pembrolizumab vs. Chemotherapy for Esophageal Cancer: Cost-Effectiveness Study | Leukemia | phase-3 | — | Source → |
| Woman develops rare condition after cancer treatment | Lung Cancer | observational | — | Source → |
| Tumour size linked to survival in lung cancer patients treated with pembrolizumab | Lung Cancer | phase-3 | The median overall survival was 18.2 months for patients with tumours larger than 86 mm, versus not reached for those with tumours 86 mm or smaller. | Source → |
| Rare Kidney Problem Linked to Cancer Treatment | Lung Cancer | observational | — | Source → |
| Researchers Report Pathological Complete Response to Pembrolizumab in Colon Cancer Patient | Colorectal Cancer | observational | — | Source → |
| Melanoma Treatment: New Options After Pembrolizumab | Melanoma | phase-3 | The overall response rate with subsequent ipilimumab was 17.5% and 30.5% with BRAF ± MEKi. | Source → |
| Combination Therapy Shows Promise for Rare Lung Cancer in Young Patients | Lung Cancer | phase-2 | — | Source → |
| Combination Therapy Shows Promise in Advanced Melanoma | Melanoma | phase-2 | ORR was 55% in PEM200+IPI50; 61% in PEM200+IPI100. | Source → |
| New Test for Lung Cancer Patients on Immunotherapy | Lung Cancer | lab-study | Patients with unfavourable changes in the hTERT cfDNA levels from baseline to 12 weeks showed a higher risk of disease progression. | Source → |
| Comparing Two Treatment Sequences for Advanced Lung Cancer | Lung Cancer | phase-2 | The objective response rate at 24 weeks in both arms was 39.5% and 40.4%, respectively. | Source → |
| Rare Skin Reaction Linked to Cancer Treatment | Melanoma | observational | — | Source → |
| Pembrolizumab Monotherapy Improves Outcomes in Lung Cancer Patients | Lung Cancer | phase-3 | Pembrolizumab improved overall survival versus chemotherapy in patients with or without baseline brain metastases: benefit was seen in patients with PD-L1 TPS ≥50% (0.67 [95% confidence intervals (CI): 0.44‒1.02] and 0.66 [95% CI: 0.58‒0.76], respectively) and PD-L1 TPS ≥1% (0.83 [95% CI: 0.62‒1.10] and 0.78 [95% CI: 0.71‒0.85], respectively). | Source → |
| Pembrolizumab with Chemotherapy in Colorectal Cancer | Colorectal Cancer | phase-2 | The primary endpoint of progression-free survival at 10 months is expected to be greater than 50%, but a 70% rate is hoped for. | Source → |
| New Way to Predict Lung Cancer Treatment Success | Lung Cancer | lab-study | Increased richness during treatment was associated with durable clinical benefit (p = 0.046), longer progression-free survival (p = 0.007) and overall survival (p = 0.05). | Source → |
| New Tool Helps Predict Lung Cancer Progression in Patients Treated with Pembrolizumab | Lung Cancer | observational | — | Source → |
| Combining Immunotherapy for Melanoma After Treatment Failure | Melanoma | phase-2 | The irRECIST response rate was 29% among the entire trial population. | Source → |
| Pembrolizumab Improves Survival in Advanced Colorectal Cancer | Colorectal Cancer | phase-3 | Median progression-free survival was 16.5 months for pembrolizumab versus 8.2 months for standard treatment. | Source → |
| Early PET Scan Results Predict Long-Term Outcome in Melanoma Patients | Melanoma | observational | — | Source → |
| Pembrolizumab Improves Quality of Life for Colorectal Cancer Patients | Colorectal Cancer | phase-3 | Least squares mean change from baseline to prespecified week 18 showed a clinically meaningful improvement in EORTC QLQ-C30 GHS/QOL scores with pembrolizumab versus chemotherapy (between-group LSM difference 8·96 [95% CI 4·24-13·69]; two-sided nominal p=0·0002). | Source → |
| Pembrolizumab Treatment Affects T Lymphocyte Subsets in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Rare Pancreatic Cancer Responds to Immunotherapy | Pancreatic Cancer | observational | — | Source → |
| Pembrolizumab's Effectiveness and Safety in Treating Melanoma | Melanoma | review | — | Source → |
| Pembrolizumab treatment stabilizes anaplastic oligodendroglioma in rare case | Leukemia | observational | — | Source → |
| Rare Eye Problem in Cancer Patient on New Treatment | Lung Cancer | observational | — | Source → |
| Pembrolizumab dosing patterns in melanoma and lung cancer | Melanoma | observational | — | Source → |
| Pembrolizumab Before Surgery for Lung Cancer: Early Results | Lung Cancer | phase-2 | Four patients (27%) presented a major pathologic response. | Source → |
| Rare Kidney Damage Linked to Cancer Treatment | Melanoma | observational | — | Source → |
| Rare Eye Inflammation Linked to Cancer Treatment | Melanoma | observational | — | Source → |
| Rare Side Effect of Cancer Treatment: Bile Duct Damage | Lung Cancer | observational | — | Source → |
| Resuming Cancer Treatment After TB Infection | Lung Cancer | observational | — | Source → |
| Long-term Safety of Pembrolizumab in Advanced Melanoma | Melanoma | phase-3 | Patients who developed immune-related side effects had similar objective response rates (64.6% versus 63.0%) and median progression-free survival (17.0 versus 17.7 months) compared to those who did not. | Source → |
| Pembrolizumab and chemotherapy improve cancer treatment for some patients | Breast Cancer | phase-3 | — | Source → |
| Combining Quavonlimab and Pembrolizumab in Lung Cancer Treatment | Lung Cancer | phase-1 | Objective response rates were 40.0% in patients receiving quavonlimab 25 mg Q3W plus pembrolizumab, 37.5% in those receiving quavonlimab 25 mg Q6W plus pembrolizumab, 27.5% in those receiving quavonlimab 75 mg Q6W plus pembrolizumab, and 35.7% in those receiving quavonlimab 75 mg Q3W plus pembrolizumab. | Source → |
| Pembrolizumab and other drugs improve cancer outcomes in melanoma patients | Melanoma | phase-2 | Median progression-free survival was 16.9 months with the combination of pembrolizumab, dabrafenib, and trametinib, compared to 10.7 months with dabrafenib and trametinib alone. | Source → |
| Pembrolizumab-based therapy for lung cancer with brain metastases | Lung Cancer | observational | Intracranial ORR was 36.4% in patients with untreated BM. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.